Redirecting to https://www.wallstreet-online.de/nachricht/20536365-eqs-news-promatix-biosciences-presents-positive-preclinical-data-with-first-in-class-pbs293-egfr-epha2-cis-bispecific-adc-demonstrating-enhanced-tumour-selectivity